



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

January 31, 2024

**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001  
Scrip Code: **533543**

**National Stock Exchange of India Ltd.**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051  
Symbol: **BROOKS**

**Sub: Outcome of Board Meeting**

**Ref: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sir/Madam,

This is with reference to the regulation mentioned above:

In continuation of our intimation dated January 24, 2024 and pursuant to Regulation 30 & Regulation 33 and other applicable regulations of the LODR, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. January 31, 2024, has inter alia approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023.

We attach herewith a copy of the approved Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2023 alongwith the Limited Review Report of the Auditors.

The meeting started at 4:30 PM and concluded at 5:50 PM.

This is for your information and record.

Thanking You,  
Yours faithfully,  
For **BROOKS LABORATORIES LIMITED**

JAI  
VAIDYA

Digitally signed  
by JAI VAIDYA  
Date: 2024.01.31  
17:54:35 +05'30'

**Jai Vaidya**  
**Company Secretary**



**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No : +91 1795 236939

**Statements of unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2023**

(Rs. In Lakhs)

Particulars	Standalone						Consolidated															
	Quarter Ended			Nine Months ended			Year Ended			Quarter Ended			Nine Months ended			Year Ended						
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	31-Dec-22	31-Mar-23							
	Unaudited			Unaudited			Audited			Unaudited			Unaudited			Audited						
<b>1 Income</b>																						
Revenue from operations	2,174.66	2,431.51	1,200.27	6,176.44	4,284.04	5,553.80	2,174.66	2,431.51	1,530.32	6,176.44	5,050.77	6,320.46										
Other Income	15.50	9.21	6.03	30.19	17.16	10.72	15.50	9.21	9.21	30.19	26.32	20.34										
<b>Total income</b>	<b>2,190.16</b>	<b>2,440.72</b>	<b>1,206.30</b>	<b>6,206.63</b>	<b>4,301.20</b>	<b>5,564.52</b>	<b>2,190.16</b>	<b>2,440.72</b>	<b>1,539.53</b>	<b>6,206.63</b>	<b>5,077.09</b>	<b>6,340.80</b>										
<b>2 Expenses</b>																						
(a) Cost of materials consumed	1,208.56	1,222.97	728.94	3,498.07	2,399.29	3,232.84	1,208.56	1,222.97	983.70	3,498.07	3,320.97	4,154.53										
(b) Purchase of Stock in Trade	289.95	362.69	83.23	738.73	553.33	611.99	289.95	362.69	63.09	738.73	428.65	487.24										
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	47.33	160.37	48.65	153.15	272.53	200.90	47.33	160.37	103.35	153.15	490.08	418.45										
(d) Employees benefits expenses	283.92	265.21	292.98	826.48	927.90	1,154.12	283.92	265.21	414.42	826.48	1,507.93	1,734.16										
(e) Finance Costs	21.29	18.67	24.02	57.07	58.24	76.67	21.29	18.67	74.76	57.07	199.89	218.32										
(f) Depreciation and amortization expenses	43.48	44.13	42.69	131.70	128.19	171.74	43.48	44.13	232.93	131.70	659.13	702.68										
(g) Other expenses	235.28	248.65	193.81	676.32	708.84	935.38	235.28	248.65	821.13	676.32	1,940.94	2,167.91										
<b>Total Expenses</b>	<b>2,129.81</b>	<b>2,322.69</b>	<b>1,414.52</b>	<b>6,081.52</b>	<b>5,048.32</b>	<b>6,383.64</b>	<b>2,129.81</b>	<b>2,322.69</b>	<b>2,593.38</b>	<b>6,081.52</b>	<b>8,547.60</b>	<b>9,883.29</b>										
<b>3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax</b>	<b>60.35</b>	<b>118.03</b>	<b>(208.22)</b>	<b>125.11</b>	<b>(747.12)</b>	<b>(819.12)</b>	<b>60.35</b>	<b>118.03</b>	<b>(1,153.85)</b>	<b>125.11</b>	<b>(3,470.51)</b>	<b>(3,542.50)</b>										
4 Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	-	-	(445.62)	(281.75)	0.35	(1,121.13)	26.86	(331.00)										
<b>Profit/(Loss) before Exceptional items</b>	<b>60.35</b>	<b>118.03</b>	<b>(208.22)</b>	<b>125.11</b>	<b>(747.12)</b>	<b>(819.12)</b>	<b>(385.27)</b>	<b>(163.71)</b>	<b>(1,153.50)</b>	<b>(996.02)</b>	<b>(3,443.65)</b>	<b>(3,873.49)</b>										
5 Exceptional items	-	-	-	-	-	-	-	-	(35.67)	-	(35.67)	(35.67)										
<b>6 Profit/(Loss) from ordinary activities before tax</b>	<b>60.35</b>	<b>118.03</b>	<b>(208.22)</b>	<b>125.11</b>	<b>(747.12)</b>	<b>(819.12)</b>	<b>(385.27)</b>	<b>(163.71)</b>	<b>(1,117.83)</b>	<b>(996.02)</b>	<b>(3,407.98)</b>	<b>(3,837.82)</b>										
<b>7 Tax Expense:</b>																						
Deferred Tax Liability / (Assets)(Refer note 6)	-	-	-	-	-	-	-	-	(169.67)	-	(732.40)	(732.40)										
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-										
Tax of earlier years	2.59	-	-	2.59	-	-	2.59	-	2.59	-	-	-										
<b>8 Net Profit/(loss) after tax</b>	<b>57.76</b>	<b>118.03</b>	<b>(208.22)</b>	<b>122.52</b>	<b>(747.12)</b>	<b>(819.12)</b>	<b>(387.86)</b>	<b>(163.71)</b>	<b>(948.16)</b>	<b>(998.61)</b>	<b>(2,675.58)</b>	<b>(3,105.42)</b>										
<b>9 Other Comprehensive Income Items That will not be reclassified into Profit or loss</b>																						
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	-	-	-	-	(4.10)	-	-	-	-	-	(4.10)										
Gain on remeasuring FVTPL financial assets	-	-	-	-	-	0.81	-	-	-	-	-	0.81										
<b>10 Total Comprehensive income for the period</b>	<b>57.76</b>	<b>118.03</b>	<b>(208.22)</b>	<b>122.52</b>	<b>(747.12)</b>	<b>(822.41)</b>	<b>(387.86)</b>	<b>(163.71)</b>	<b>(948.16)</b>	<b>(998.61)</b>	<b>(2,675.58)</b>	<b>(3,108.71)</b>										
<b>Net Profit attributable to</b>																						
Owners of equity	-	-	-	-	-	-	-	-	(501.90)	-	(1,660.15)	(2,090.01)										
Non Controlling Interest	-	-	-	-	-	-	-	-	(446.26)	-	(1,015.43)	(1,015.41)										
<b>Other Comprehensive Income attributable to :</b>																						
Owners of equity	-	-	-	-	-	-	-	-	-	-	-	(3.29)										
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-										
<b>Total Comprehensive Income attributable to</b>																						
Owners of Equity	-	-	-	-	-	-	-	-	(501.90)	-	(1,660.15)	(2,093.30)										
Non Controlling Interest	-	-	-	-	-	-	-	-	(446.26)	-	(1,015.43)	(1,015.41)										
<b>11 Paid-up equity share capital (Face Value of Rs. 10 each)</b>	<b>2,624.67</b>	<b>2,624.67</b>	<b>2,470.28</b>	<b>2,624.67</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,624.67</b>	<b>2,624.67</b>	<b>2,470.28</b>	<b>2,624.67</b>	<b>2,470.28</b>	<b>2,470.28</b>										
<b>12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.</b>	<b>3,207.61</b>	<b>3,207.61</b>	<b>4,030.03</b>	<b>3,207.61</b>	<b>4,030.03</b>	<b>4,030.03</b>	<b>4,925.05</b>	<b>4,925.05</b>	<b>6,278.72</b>	<b>4,925.05</b>	<b>6,278.72</b>	<b>6,278.72</b>										
<b>13 Earnings per share (of Rs. 10/- each) (not annualised)</b>																						
(a) Basic	0.23	0.46	(0.84)	0.48	(3.02)	(3.32)	(1.51)	(0.64)	(2.03)	(3.90)	(6.72)	(12.57)										
(b) Diluted	0.23	0.46	(0.84)	0.48	(3.02)	(3.32)	(1.51)	(0.64)	(2.03)	(3.90)	(6.72)	(12.57)										




**Notes:**

- 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 31st January 2024
- 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- 3 The Board of Directors at its meeting held on July 18, 2023, has inter alia considered and approved the rights issue of 15,43,926 fully paid-up Equity Shares of Rights issue price of Rs.75 per equity share [including a premium of Rs. 65 per Equity Share] for amount aggregating up to Rs. 1,157.94 lakhs. Subsequently, Rights Issue Letter of Offer (LoF) was filed on August 1, 2023 with BSE Limited (BSE), August 2, 2023 with National Stock Exchange of India Limited (NSE) and August 3, 2023 with Securities and Exchange Board of India (SEBI). The company has allotted the shares on 28th August 2023. The Right Issue proceeds were fully utilised for objects mentioned in Letter of offer dated July 18, 2023.
- 4 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 5 During the Quarter Ended December 31, 2022 the company has lost control over its own subsidiary company Brooks Steriscience Limited (BSL) and the company now jointly controls the entity along with its JV partner and has accounted accordingly subsequent to loss of control. Hence the current year quarter figures are not comparable with previous year quarter figures.
- 6 In the absence of future taxable profit, The Company has not recognised deferred tax asset on its business losses/depreciation in accordance with Ind As 12 "Income taxes"
- 7 The Company operates in one reportable business segment i.e. "Pharmaceuticals".
- 8 Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board



**JITENDRAPRATAP RAMBAHADUR SINGH**  
Din : 09796568  
Wholetime Director



Place : Baddi  
Date : 31st January 2024

# **SGCO & Co. LLP**

**Chartered Accountants**

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter and nine months ended on December 31, 2023, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,  
The Board of Directors of  
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter and nine months ended on December 31, 2023. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 112081W/W100184

  
**Suresh Murarka**

Partner

Mem. No. 044739

UDIN: 24044739BKARIZ2569

Place: Mumbai

Date: 31<sup>st</sup> January 2024



4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. [info@sgco.co.in](mailto:info@sgco.co.in)  
[www.sgco.co.in](http://www.sgco.co.in)

# **SGCO & Co. LLP**

**Chartered Accountants**

Limited Review Report on Unaudited Consolidated Financial Results Brooks Laboratories Limited for the quarter and nine months ended December 31 2023 of pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
**Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its Jointly controlled entity and associate for the quarter and nine months ended December 31, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- i. Brooks Laboratories Limited (Parent Company)
- ii. Brooks Steriscience Limited (Jointly Controlled Entity)
- iii. Steribrooks Penems Private Limited (Associate Company)



4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. [info@sgco.co.in](mailto:info@sgco.co.in)  
[www.sgco.co.in](http://www.sgco.co.in)

# SGCO & Co. LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of Jointly Controlled Entity vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial statement include the Group share of net loss of Rs. 445.22 Lakhs and 1120.73 lakhs for the quarter and nine months ended December 31, 2023, respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Jointly controlled entity, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

The consolidated financial statements also includes the Group's share of net loss of Rs. 0.40 Lakhs and Rs. 0.40 Lakhs for the quarter and nine months ended December 31, 2023, as considered in the consolidated unaudited financial statements, in respect of associate Steribrooks Penems Private Limited whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management.

Our conclusion on the Statement is not modified in respect of the above matters.

**For S G C O & Co. LLP**

Chartered Accountants

**Firm Registration No. 112081W/W100184**



**Suresh Murarka**

Partner

**Mem. No. 44739**

**UDIN: 24044739BKARJA9840**

Place: Mumbai

Date: 31st January 2024

